EUCTR2010-022054-16-DE进行中（未招募）不适用
ong-term effects of Aldara® 5% cream andSolaraze® 3% gel in the treatment of actinic keratoseson the face or scalp with respect to the risk ofprogression to in-situ and invasive squamous cellcarcinoma (LEIDA 2) - LEIDA 2
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Immunocompetent patient.
- •2. A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area.
- •3. A positive histological finding for AK grade I or II (see Section 7.1.1.2). This will be determined from the most suspicious lesion in the STA and there from the most pathological area biopsied during screening visit. This analysis will be done by the central histopathological laboratory.
- •4. Willingness to comply with the obligations of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •1. History of hypersensitivity to imiquimod, diclofenac, acetyl salicylic acid, other
- •non-steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients.
- •2. Pregnancy, breast-feeding or planned pregnancy during the study. Women of child
- •bearing potential not using a highly effective method of birth control defined as those
- •which result in a low failure rate (i.e. <1% per year) when used consistently and correctly
- •such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation
- •or vasectomised partner.
- •Lack of suitability for the study:
- •3. Presence of AK lesions in the STA with clinically excessive hyperkeratosis as seen in
- •cutaneous horns.
- •4. Any topical AK treatment including imiquimod or diclofenac, or any systemic AK
- •treatment such as systemic retinoids, or any surgical AK treatment at the STA within the
- •last 2 months prior to randomisation.
- •5. Persisting AK lesion at screening visit following topical treatment with imiquimod or
- •diclofenac in the STA.
- •6. Presence of any histologically confirmed skin tumour in the STA: in situ SCC including
- •Bowen’s disease, invasive SCC, basal cell carcinoma, or other malignant tumours.
- •7. Any dermatological disease or condition that may exacerbate by treatment with
- •imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis).
- •8. Any dermatological disease or condition in the STA that causes difficulty with
- •examination (e.g. eczema).
- •9. Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine,
- •retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids with
- •dosages of >1200 µg/day beclomethasone or equivalent within 4 weeks before start of
- •study treatment.
- •10. History of any malignant tumour with high tumour burden or any systemic antitumour
- •treatment (incl. radiotherapy).
- •11. History of any malignant skin tumour having metastasised or in which metastasis within
- •the study period is likely.
- •12. History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal,
- •haematological, endocrine, metabolic, mental, neurological, or other disease within the
- •last two years which might hinder regular treatment and supervision and might lead to
- •premature withdrawal from the study.
- •13. Mentally incapacitated patient.
- •14. Present or history of drug or alcohol abuse within the last 3 years.
- •Administrative reasons:
- •15. Exposure to an investigational product within the last 3 months.
- •16. Lack of ability or willingness to give informed consent.
- •17. Age below 18 years.
- •18. Lack of willingness to have personal study related data collected, archived or transmitted
- •according to protocol.
- •19. Anticipated non-availability for study visits/procedures.
- •20. Vulnerable subjects (such as persons kept in detention).
研究者
相似试验
进行中（未招募）
不适用
ong-term effects of Aldara® 5% cream compared toSolaraze® 3% gel in the treatment of actinic keratoseson the face or scalp.EUCTR2010-022054-16-ATMEDA Pharma GmbH & Co. KG220
进行中（未招募）
不适用
ong-term effects of Aldara® 5% cream compared toSolaraze® 3% gel in the treatment of actinic keratoseson the face or scalp.This study will compare the long term effects of Aldara® and Solaraze® of the actinic keratoses on the face or scalp. Actinic keratoses (AKs) are defined as keratotic macules, papules or plaques with superficial scale on a red base, occurring on areas of extensive damage through sunlight. AKs are mainly induced by non-ionised radiation, especially through chronic UV-exposition, primarily sunlight.MedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2007-004884-24-ATMEDA Pharma GmbH & Co. KG240
进行中（未招募）
1 期
ong-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA) - LEIDA (Long-term effects of Imiquimod and Diclofenac in Actinic keratoses)This study will investigate the long term effects of Aldara® and Solaraze® on Actinic keratoses (AKs) on the face or scalp. AKs are defined as keratotic macules, papules or plaques with superficial scale on a red base, occurring on areas of extensive damage through sunlight. AKs are mainly induced by non-ionised radiation, especially through chronic UV-exposition, primarily sunlight.MedDRA version: 9.1Level: LLTClassification code 10000614Term: Actinic keratosisEUCTR2007-004884-24-FRMEDA Pharma GmbH & Co. KG
进行中（未招募）
不适用
ong-term effects of Aldara® 5% cream compared to Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp.This study will compare the long term effects of Aldara® and Solaraze® of the actinic keratoses on the face or scalp. Actinic keratoses (AKs) are defined as keratotic macules, papules or plaques with superficial scale on a red base, occurring on areas of extensive damage through sunlight. AKs are mainly induced by non-ionised radiation, especially through chronic UV-exposition, primarily sunlight.MedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2007-004884-24-DEMEDA Pharma GmbH & Co. KG240
已完成
4 期
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)Actinic KeratosisNCT01453179MEDA Pharma GmbH & Co. KG221